BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 19423543)

  • 1. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
    Mave V; Garcia-Diaz J; Islam T; Hasbun R
    J Antimicrob Chemother; 2009 Jul; 64(1):175-80. PubMed ID: 19423543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
    Erlandson KM; Sun J; Iwen PC; Rupp ME
    Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.
    Crank CW; Scheetz MH; Brielmaier B; Rose WE; Patel GP; Ritchie DJ; Segreti J
    Clin Ther; 2010 Sep; 32(10):1713-9. PubMed ID: 21194593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
    King EA; McCoy D; Desai S; Nyirenda T; Bicking K
    J Antimicrob Chemother; 2011 Sep; 66(9):2112-8. PubMed ID: 21697178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
    Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
    Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan.
    Chou CH; Lee NY; Lee HC; Chang CM; Lee CC; Ko WC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):221-7. PubMed ID: 22578639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
    Grau S; Rebollo P; Cuervo J; Gil-Parrado S
    Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF; Friedrich LV; Yankelev S; Lamp KC
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
    Shorr AF; Kunkel MJ; Kollef M
    J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin.
    Twilla JD; Finch CK; Usery JB; Gelfand MS; Hudson JQ; Broyles JE
    J Hosp Med; 2012 Mar; 7(3):243-8. PubMed ID: 22076962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.
    Chuang YC; Wang JT; Lin HY; Chang SC
    BMC Infect Dis; 2014 Dec; 14():687. PubMed ID: 25495779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with daptomycin: bacteraemia and endocarditis.
    Levine DP
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M; Nathwani D; Dryden M
    J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.
    Balli EP; Venetis CA; Miyakis S
    Antimicrob Agents Chemother; 2014; 58(2):734-9. PubMed ID: 24247127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium.
    Mueller SW; Kiser TH; Anderson TA; Neumann RT
    Ann Pharmacother; 2012 Dec; 46(12):e35. PubMed ID: 23232018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and clinical outcome of enterococcal bacteraemia in an acute care hospital.
    Poh CH; Oh HM; Tan AL
    J Infect; 2006 May; 52(5):383-6. PubMed ID: 16203039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.
    Shukla BS; Gauthier TP; Correa R; Smith L; Abbo L
    Int J Clin Pharm; 2013 Oct; 35(5):697-703. PubMed ID: 23893061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.